Hypovitaminosis D
Conditions
Brief summary
Hypovitaminosis D is common in the adult population, it affects at least 1 billion people worldwide, and in particular 80% of the French population according to the National Institute for Public Health Surveillance. Hypovitaminosis D is accompanied or complicated by deleterious health manifestations such as bone, immune and cancer diseases, neuromuscular disorders and a propensity to fall, for example. Hypovitaminosis D has also been associated with more complicated care pathways (increase in the severity of the reason for hospitalization, length of hospitalization, risk of in-hospital death). Prevention of these clinical events depends on correcting vitamin D status. In sick, dependent or fragile adults, natural intakes are generally insufficient. It is indeed accepted that hypovitaminosis D may not be treated effectively by dietary measures or by simple exposure to the sun in French latitudes. Drug supplementation is therefore necessary, with the objective of achieving a target concentration of circulating 25-hydroxyvitamin D (25 (OH) D) of 75 nmol / L (30 ng / mL) in this population. Vitamin D supplementation, when properly conducted, corrects hypovitaminosis D, and has been associated with improved prognosis, especially life-saving, in therapeutic trials versus placebo. Such results lead the investigators to suggest that the identification and correction of hypovitaminosis D in hospitalized patients could represent a simple, effective and inexpensive strategy for improving hospital care pathways. In this perspective, the first step is to determine the prevalence, severity and clinical profile of hospitalized patients with hypovitaminosis D, as well as their course of care. To the investigators knowledge, there are no large-scale studies based on real-life data on this subject.
Interventions
None listed
Sponsors
University Hospital, Angers
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years old * have had a dosage of circulating 25-hydroxyvitamin D (plasma or serum) in a HUGO establishment * consultant or hospitalized between 01/01/2015 and 12/31/2019 in one of the participating HUGOs.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence and depth of hypovitaminosis D | baseline | the prevalence of hypovitaminosis D will be calculated for each of the 3 definition thresholds for hypovitaminosis D found in the literature: ≤ 75 nmol/L, ≤ 50 nmol/L and ≤ 25 nmol/L. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical profile | baseline | The clinical profile will be determine by the data provided by the physician during the hospitalization or the consultation |
| Length of hospitalisation | baseline | determine whether the circulating 25-hydroxyvitamin D concentration is associated with the length of hospitalization in days |
| Mortality | baseline, 14 and 28 days, 3 and 6 months after the dosage | determine whether the circulating 25-hydroxyvitamin D concentration is associated with the death occurring during hospital stay. |
Contacts
Primary ContactCédric ANNWEILER, MD,PhD
Outcome results
None listed